Navigation Links
Compendia Bioscience Releases Oncomine Concepts Edition 4.0
Date:3/26/2009

With User Inspired Features and a Redesigned Interface, Oncomine Remains Data-Focused

ANN ARBOR, Mich., March 26 /PRNewswire-USNewswire/ -- Compendia Bioscience announces the release of Oncomine Concepts Edition version 4.0, the latest incarnation of the company's flagship product. Since its inception at the University of Michigan, Oncomine has been rapidly adopted by drug discovery and development organizations looking to improve results of cancer drug development efforts. This new version of Oncomine features an improved user-interface and new export function that allows results sharing.

Cancer researchers and drug developers have made Oncomine the industry-standard, with 15 of the top 20 cancer research companies using this product for interactive access and in-depth analysis of curated cancer genomics data. Oncomine has led to several major cancer research discoveries such as the presence of gene fusions in the majority of prostate cancers (Cancer Cell, Volume 13 Issue 6: June 2008. Nature, Aug 2 2007).

"In accumulating so much high-value data, our biggest success has created our biggest challenge," commented Compendia CEO and Co-founder Dan Rhodes, Ph.D. "It has become difficult to navigate all of the data and analyses to answer the burning questions at hand. Oncomine Concepts Edition 4.0 makes these efforts more intuitive and much, much easier."

New Functionality in Oncomine Concepts Edition 4.0

  • Implementation of the Compendia Ontology - a multi-threaded tree of terms that facilitates searching and browsing data
  • Smart search - the ability to include as many genes as desired in a search request as well as an auto-complete feature using terms from the Compendia Ontology
  • Unified user interface - the ability to view the list of results and individual visualizations within a single browser window
  • Seamless integration of Oncomine Concepts Map - linking drugs, tumor types and biology to sets of genes without leaving the main interface
  • Bookmarks - the ability to save specific searches, results sets or analyses for later review or to share with other Oncomine users
  • Export - the ability to rapidly export results and visualizations to Excel and PowerPoint for further analysis or to share with colleagues

While improved user experience was the driving force in Oncomine Concepts Edition 4.0, the entire Oncomine database was also scrutinized in an effort to standardize and catalog all data points. Oncomine Research Edition 4.0 will be released in the later part of 2009.

About Compendia Bioscience, Inc.

Compendia Bioscience is dedicated to harnessing the global collection of high throughput molecular data to provide researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes. www.compendiabio.com

About Oncomine(TM)

Oncomine combines a rapidly growing compendium of 30,000+ expertly curated cancer genomic profiles with a sophisticated analysis engine and a powerful web application for data mining and visualization. Oncomine facilitates target discovery and validation and supports the prioritization of tumor populations for drug development. http://www.compendiabio.com/products/products.htm

    For additional information regarding this announcement, please contact:
    John Freshley
    Chief Business Officer
    Compendia Bioscience
    Phone: (734) 945-6344
    E-mail: media@compendiabio.com


'/>"/>
SOURCE Compendia Bioscience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
3. Professionals in bioscience, food-related industries turn to K-State
4. Aeon Bioscience Continues Development of Drug Eluting Stents
5. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
6. Forest Laboratories and Cypress Bioscience to Host Webcast to Discuss Clinical Data Presentations for Milnacipran
7. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
8. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
9. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
10. Anaptys Biosciences Raises Over $33 Million in Series B Financing
11. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 26, 2016 One of Australia,s ... the formation of a new biotechnology company, Noxopharm Limited [ABN 50 ... an IPO and to list on the ASX. Noxopharm ... ready to enter a Phase 1 clinical study later this year. ... address one of the biggest problems facing cancer patients - the ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
Breaking Medicine Technology: